Browse > Article
http://dx.doi.org/10.4062/biomolther.2009.17.4.388

Effects of Anti-Asthma Agents on Cytokine and Prostaglandin Production in Ovalbumin-Sensitized Splenocytes  

Won, Tae-Joon (Department of Immunology, College of Pharmacy, Chung-Ang University)
Lee, Chan-Woo (Department of Immunology, College of Pharmacy, Chung-Ang University)
Kwon, Seok-Joong (Department of Immunology, College of Pharmacy, Chung-Ang University)
Lee, Do-Ik (Department of Immunology, College of Pharmacy, Chung-Ang University)
Park, So-Young (Environmental Toxico-genomic and Proteomic Center, College of Medicine, Korea University)
Hwang, Kwang-Woo (Department of Immunology, College of Pharmacy, Chung-Ang University)
Publication Information
Biomolecules & Therapeutics / v.17, no.4, 2009 , pp. 388-394 More about this Journal
Abstract
The cytokines which is produced by allergen-specific T helper (Th) cells play a pivotal role in the pathogenesis of asthma. Asthma is caused by exaggerated T-helper 2 (Th2)-based immune responses. It is suggested that controlling such Th2-based response is necessary for asthma therapy. The current therapies for asthma focus primarily on control of symptoms and suppression of inflammation, without affecting the underlying cause. So, we examined that anti-asthmatic drugs might have play a certain role in Th2/Th1 balance. Splenocytes isolated from ovalbumin (OVA)-sensitized mice cultured with anti-asthmatic drugs. It is well known that Th2 and Th1 immune responses can balance one another, as Th2 mediators suppress Th1 responses and Th1 mediators similarly inhibit Th2 responses. But salmeterol inhibits both of Th1 and Th2 mediators, which salmeterol is a suppressor of immune responses not only a suppressor of Th2-based immune responses. Aminophylline is a weak suppressor of immune responses. But ipratropium and cromoglycate don't have any suppressor effect to Th2-driven responses. They only have suppressor effect to Th1 immune responses. Salmeterol, ipratropium, aminophylline, and cromoglycate augmented mRNA levels of CRTH2, EP2, and IP2 receptors in OVA-sensitized splenocytes. It is well known that the up-regulation of CRTH2 - $PGD_2$ receptor - results in restraint of eosinophil recruitment and that the increment of IP and EP2 - $PGI_2$ and $PGE_2$ receptor, respectively - may induce the accumulation of cAMP that decrease the effector function of T cells. Moreover salmeterol and cromoglycate increase the mRNA expression of $PGD_2$ synthase. These findings indicate that anti-asthma agents may alleviate the immunological responses that cause the asthmatic diseases.
Keywords
Asthma; Ovalbumin; BALB/c mice; T helper 2 cell; Cytokines; Prostaglandins;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Black, J. L., Armour, C. L., Vincenc, K. S. and Johnson, P. R. (1986). A comparison of the contractile activity of PGD2 and PGF2 alpha on human isolated bronchus. Prostaglandie 32, 25-31.   DOI   ScienceOn
2 Matsuoka, T., Hirata, M., Tanaka, H., Takahashi, Y., Murata, T., Kabashima, K., Sugimoto, Y., Kobayashi, T., Ushikubi, F., Aze, Y., Eguchi, N., Urade, Y., Yoshida, N., Kimura, K., Mizoguchi, A., Honda, Y., Nagai, H. and Narumiya, S. (2000). Prostaglandin D2 as a mediator of allergic asthma. Science. 287, 2013-2017.   DOI   ScienceOn
3 Oh, J. W., Lee, H. B., Chung, Y. H. and Choi, Y. (2002). The effect of disodium cromoglycate, budesonide, and cyclosporin A on interleukin-4, interleukin-5, and interleukin-13 secretions in Der p I-stimulated T cells from house dust mite-sensitive atopic and nonatopic individuals. Allergy Asthma Proc. 23, 109-115.
4 Takahashi, Y., Tokuoka, S., Masuda, T., Hirano, Y., Nagao, M., Tanaka, H., Inagaki, N., Narumiya, S. and Nagai, H. (2002). Augmentation of allergic inflammation in prostanoid IP receptor deficient mice. Br. J. Pharmacol. 137, 315-322.   DOI   ScienceOn
5 Umetsu, D. T. and DeKruyff, R. H. (1997). Th1 and Th2 CD4+ cells in human allergic diseases. J. Aller. Clin. Immunol. 100, 1-6.   DOI   ScienceOn
6 Wenzel, S. E., Westcott, J. Y. and Larsen, G.L. (1991). Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses. J. Allergy Clin. Immunol. 87, 540-548.   DOI
7 Wills-Krap, M, Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., and Donaldson, D. D. (1998). Interleukin-13: central mediator of allergic asthma. Science. 282, 2258-2261.   DOI   ScienceOn
8 Nagai, H., Arimura, A., Yoshitake, K., Iwama, T., Sakurai, T. and Koda, A. (1993). The effect of a novel thromboxane A2 (TXA2) receptor antagonist (S-1452) on the antigen-induced bronchoconstriction and airway hyperresponsiveness in guinea pigs. Prostaglandins Leukot Essent Fatty Acids. 48, 343-349.   DOI   ScienceOn
9 Miadonna, A., Tedeschi, A., Brasca, C., Folco, G., Sala, A. and Murphy, R. C. (1990). Mediator release after endobronchial antigen challenge in patients with respiratory allergy. J. Allergy Clin. Immunol. 85, 906-913.   DOI
10 Mohede, I. C., Van Ark, I., Brons, F. M., Van Oosterhout, A. J. and Nijkamp, F. P. (1996). Salmeterol inhibits interferongamma and interleukin-4 production by human peripheral blood mononuclear cells. Int. J. Immunopharmacol. 18, 193-201.   DOI   ScienceOn
11 Nagata, K., Tanaka, K., Ogawa, K., Kemmotsu, K., Imai, T., Yoshie, O., Abe, H., Tada, K., Nakamura, M., Sugamura, K. and Takano, S. (1999). Selective expression of a novel surface molecule by human Th2 cells in vivo. J. Immunol. 162, 1278-1286.
12 Narumiya, S., Sugimoto, Y. and Ushikubi, F. (1999). Prostanoid receptors: structures, properties, and functions. Physiol Rev. 79, 1193-1226.   DOI
13 Nauta, A. J., Engels, F., Knipples, L. M., Garssen, J., Nijkamp, F. P. and Redegeld, F. A. (2008). Mechanisms of allergy and asthma. Eur. J. Pharmacol. 585, 354-360.   DOI   ScienceOn
14 Marom, Z., Shelhamer, J.H. and Kaliner, M. (1981). Effects of arachidonic acid, monohydroxyeicosatetraenoic acid and prostaglandins on the release of mucous glycoproteins from human airways in vitro. J. Clin. Invest. 67, 1695-1702.   DOI
15 Peters, S. P. (2003). Heterogeneity in the pathology and treatment of asthma. Am. J. Med. 115(Suppl 3A), 49S-54S.   DOI   ScienceOn
16 Sturm, E. M., Schratl, P., Schuligoi, R., Konya, V., Sturm, G. J., Lippe, I. T., Peskar, B. A. and Heinemann, A. (2008). Prostaglandin E2 inhibits eosinophil trafficking through Eprostanoid 2 receptors. J. Immunol. 181, 7273-7283.   DOI
17 Houtman, R. and van den Worm, E. (2005). Asthma, the ugly duckling of lung disease proteomics? J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 815, 285-294.   DOI   ScienceOn
18 Leal-Berumen, I., O'Byrne, P., Gupta, A., Richards, C. D. and Marshall J. S. (1995). Prostanoid enhancement of interleukin- 6 production by rat peritoneal mast cells. J Immunol. 154, 4759-4767.
19 Matsuo, N., Shimoda, T., Matsuse, H., Obase, Y., Asai, S. and Kohno, S. (2000). Effects of sodium cromoglycate on cytokine production following antigen stimulation of a passively sensitized human lung model. Ann. Allergy Asthma Immunol. 84, 72-78.   DOI   ScienceOn
20 Turner, N. C., Fuller, R. W. and Jackson, D. M. (1995). Eicosanoid release in allergen-induced bronchoconstriction in dogs. Its relationship to airways hyperreactivity and pulmonary inflammation. J. Lipid Mediat. Cell Signal. 11, 93-102.   DOI   ScienceOn